Smith+Nephew (NYSE:SNN) announced this week that it launched its Journey II Rox total knee solution, a reverse hybrid construct for total knee arthroplasty.
The company designed the orthopedic device to give surgeons the clinical advantage of advanced bearing material and anatomic design combined with the efficiency and potential long-term tibia fixation of cementless knees.
Journey II Rox has several combinations of S+N’s high-performance technologies in one construct, including the characteristics kinematics of Journey II TKA, the clinical history of Conceloc Advanced Porous Titanium and the wear resistance of Oxinium Oxidized Zirconium. The total knee system is compatible with Smith+Nephew’s Cori surgical robotic system.
“The reverse hybrid combination provides my patients with a powerful collection of knee arthroplasty technologies. The kinematic functionality of Journey II, the biocompatibility and longevity benefits of an oxidized zirconium alloy femoral component in Oxinium and now Conceloc,” Dr. Steven Haas, chair of knee surgery at the Hospital for Special Surgery in New York, said in a news release. “Conceloc offers the potential to achieve osseointegration where it is needed — the tibia and patellae. It’s an evidence-based approach to knee arthroplasty that utilizes high-performance technologies delivered with the operative time savings recognized in a complete cementless procedure.”
The reverse hybrid technique of the Journey II Rox total knee solution allows doctors to use the mechanics for a more natural knee function.
“Driving procedural innovation to help surgeons treat patients and provide better outcomes is the core of our purpose — Life Unlimited,” Executive VP and GM of Global Joint Reconstruction at Robotics Randy Kilburn said. “The Journey II Rox Total Knee Solution underscores this by bringing together high-performance components to deliver a custom procedural solution that no other company offers.”